| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
This compound does not possess a specific biological target; its primary function is as a chemical building block for peptide synthesis. The Fmoc group provides base-labile Nα-protection, while the tert-butyl group provides acid-labile side-chain protection. The 3-fluoro substitution confers distinct physicochemical properties to the resulting peptides compared to canonical tyrosine, including altered phenolic pKa, enhanced metabolic stability against proteolytic degradation, and a 19F NMR spectroscopic handle.
|
|---|---|
| ln Vitro |
This compound is not a biological agent and does not exhibit direct in vitro biological activity in a pharmacological sense. Its value lies in its chemical utility as a protected amino acid building block. It is described as a cyclic peptide compound with high membrane permeability and specific binding affinity towards a target molecule, but this bioactivity is associated with the final peptide products, not the protected intermediate itself.
|
| ln Vivo |
Fmoc-Tyr(3-F,tBu)-OH is not administered in vivo as a therapeutic agent. It is a research chemical utilized as a building block in peptide synthesis. The final deprotected peptide product, not this protected intermediate, would be the subject of in vivo pharmacological testing. The compound is for research use only and is not intended for human or veterinary therapeutic applications.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays are not applicable to Fmoc-Tyr(3-F,tBu)-OH as it is not biologically active. Its use is in organic synthesis and peptide chemistry. A typical protocol involves its use as a building block in Fmoc SPPS, where the Fmoc group is removed with a base (e.g., piperidine) to allow for coupling with the next amino acid using standard coupling reagents. The 3-fluoro substitution provides a 19F NMR handle for structural studies.
|
| Cell Assay |
This compound is not used in cell-based assays as a therapeutic agent. Its applications are in synthetic chemistry and peptide synthesis. It should be stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years; in solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month. It has a computed LogP of 5.7. The product is for research purposes only and is not intended for human or veterinary use.
|
| Animal Protocol |
In vivo animal experiments do not involve Fmoc-Tyr(3-F,tBu)-OH as a test article. It is a chemical intermediate used in the synthesis of peptide-based drug candidates. If a researcher synthesizes a therapeutic peptide using this building block, that final deprotected and purified peptide product would be subjected to animal testing for pharmacokinetics, efficacy, and toxicity. The protected amino acid itself is never administered to animals as a test compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable to Fmoc-Tyr(3-F,tBu)-OH as it is not a drug. It is a small molecule (MW 477.5 g/mol) with the formula C28H28FNO5. Its properties are relevant for chemical handling and storage rather than for systemic exposure studies. The compound is not designed to be bioavailable, as the Fmoc and tBu protecting groups are intended to be removed during peptide synthesis to yield the final active peptide product.
|
| Toxicity/Toxicokinetics |
The toxicity of Fmoc-Tyr(3-F,tBu)-OH is not extensively documented, as it is a research chemical not intended for human or veterinary use. As with all Fmoc-protected amino acids, standard laboratory safety precautions should be followed, including handling in a well-ventilated area with appropriate personal protective equipment. It should be stored as a powder at -20°C or 4°C and protected from moisture. It is not intended for diagnostic, therapeutic, or other medical applications.
|
| References |
[1]. Tanada, Mikimasa, et al. Cyclic peptide compound having high membrane permeability, and library containing same. Patent WO2018225864A1.
|
| Additional Infomation |
Fmoc-Tyr(3-F,tBu)-OH is a protected, non-canonical amino acid derivative of L-tyrosine featuring an Fmoc group on the α-amino terminus, a tBu protecting group on the phenolic oxygen, and a fluorine substituent at the 3-position of the aromatic ring. The 3-fluoro substitution confers distinct physicochemical properties, including altered phenolic pKa and a 19F NMR spectroscopic handle. This compound belongs to the Fmoc/tBu orthogonal protection strategy class. It is not a pharmaceutical.
|
| Molecular Formula |
C28H28FNO5
|
|---|---|
| Molecular Weight |
477.524031639099
|
| Exact Mass |
477.195
|
| CAS # |
2254698-84-3
|
| PubChem CID |
142490636
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.7
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
35
|
| Complexity |
717
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC1C=C(C=CC=1OC(C)(C)C)C[C@@H](C(=O)O)NC(=O)OCC1C2C=CC=CC=2C2=CC=CC=C12
|
| InChi Key |
ZLZOTVKOIDTAHM-DEOSSOPVSA-N
|
| InChi Code |
InChI=1S/C28H28FNO5/c1-28(2,3)35-25-13-12-17(14-23(25)29)15-24(26(31)32)30-27(33)34-16-22-20-10-6-4-8-18(20)19-9-5-7-11-21(19)22/h4-14,22,24H,15-16H2,1-3H3,(H,30,33)(H,31,32)/t24-/m0/s1
|
| Chemical Name |
(2S)-2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-[3-fluoro-4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0942 mL | 10.4708 mL | 20.9415 mL | |
| 5 mM | 0.4188 mL | 2.0942 mL | 4.1883 mL | |
| 10 mM | 0.2094 mL | 1.0471 mL | 2.0942 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
